ClinicalTrials.gg
CompletedNCT00368251Updated May 31, 2023Results posted

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

A Phase 3 interventional study of Placebo and BRV 2.5 mg in Unverricht-Lundborg Disease, sponsored by UCB Pharma. Completed at 18 sites in 8 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Myoclonus with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Myoclonus · United States.

Started
2006
the only one that year
Phase 3
Only one
of the 13
Registered
8th of 13
by date
Lead sponsor
1 of 13
UCB Pharma

Among the 13 studies in Myoclonus with a site in United States, this one is the only one that started in 2006, is the only one in phase 3, and was the 8th registered.

Myoclonus

20 studies on the registry are indexed under Myoclonus; 6 are open to participants now.

Browse Myoclonus studies →

Open to participants now

6 of the 13 studies in Myoclonus with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myoclonus studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myoclonus with a site in United States, or all of them as a file.
02

Study summary

The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).

03

Conditions studied

  • Unverricht-Lundborg Disease

Browse trials for

Keywords

  • Unverricht-Lundborg Disease
  • Baltic Myoclonus
  • Progressive Myoclonic Epilepsies
  • Myoclonus
  • Brivaracetam
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with diagnosed Unverricht-Lundborg disease (ULD) ascertained by appropriate genetic testing for a homozygous or compound heterozygous mutation in the CSTB gene- Subjects with moderate to severe myoclonus documented by an Action Myoclonussum score of ≥ 30 (evaluation by investigator)-Subjects currently being or having been treated with clonazepam up to the maximum recommended daily dose of 20 mg or up to their individual optimal dose as assessed by the investigator- Subjects currently being or having been treated with valproate up to the maximum recommended daily dose 60 mg/kg or serum levels of 100 mcg/ml or up to their individual optimal dose as specified by the investigator- Male/female subjects from 16 years onwards. Subjects under 18 years may only be included where legally permitted and ethically accepted

Exclusion criteria

Exclusion Criteria:

  • Subjects currently on felbamate or having been on felbamate within less than 18 months prior to Visit 1- Subjects currently treated with phenytoin or having been on phenytoin in the last month prior to Visit 1- Subjects currently on vigabatrine. Subjects having been on vigabatrine if no visual fields examination report available including standard static (Humphrey or Octopus) or cinetic perimetry (Goldman)- Subject taking any drug with possible central nervous system (CNS) effects- Subjects taking any drug that may significantly influence the metabolism of BRV (CYP2C or potent inducers/inhibitors)- Known acute or chronic illness or illness which may impair reliable participation in the trial, necessitate the use of medication not allowed by protocol or represent a safety risk in the Investigator's opinion- Subjects with history of severe adverse hematological reaction to any drug- Impaired hepatic function: ALAT/, ASAT/SGOT, alkaline phosphatase, GGT value of more than three times the upper limit of the reference range- History of suicide attempt during the last 5 years- Subject with suicidal ideations within the last year or at risk of suicide attempt unless cleared by written confirmation from a psychiatrist and approved by the UCB physician- Ongoing psychiatric disorder other than mild controlled disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)

    Other: Placebo

  • Experimental
    Brivaracetam 5 mg/day

    Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)

    Drug: BRV 2.5 mg

  • Experimental
    Brivaracetam 150 mg/day

    Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)

    Drug: BRV 25 mg · Drug: BRV 50 mg

Interventions

  • OtherPlacebo

    * Pharmaceutical Form: Tablet * Concentration: 2.5 mg, 25 mg and 50 mg * Route of Administration: Oral use

  • * Pharmaceutical Form: Tablet * Concentration: 2.5 mg * Route of Administration: Oral use

    Also known as: ucb34714

  • DrugBRV 25 mg

    * Pharmaceutical Form: Tablet * Concentration: 25 mg * Route of Administration: Oral use

  • DrugBRV 50 mg

    * Pharmaceutical Form: Tablet * Concentration: 50 mg * Route of Administration: Oral use

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)

    The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

    Time frame: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

Secondary outcomes

  1. Percent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5)

    The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

    Time frame: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

  2. Percent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3)

    The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

    Time frame: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

  3. Percent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1)

    The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

    Time frame: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

  4. Global Evaluation Score (Investigator) at the End of Treatment Period

    The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement).

    Time frame: End of Treatment Period (Week 14 or Early Discontinuation Visit)

07

Results

Posted Apr 13, 2016

Participant flow

72 subjects were screened, 56 subjects were randomized. Participant Flow refers to all subjects randomized who are identical with the Intent-To-Treat (ITT) Population, which consists of all randomized subjects who took at least one dose of study medication.

Participant flow — Overall Study
MilestonePlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
Started182018
Completed172017
Not completed101
Withdrew: Sae, non-fatal100
Withdrew: Ae, non-serious non-fatal001

Outcome measures

PrimaryPercent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)

The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

Time frame:
From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Reported as:
Median · Percent change
Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)
Percent changePlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)17.45 (-170.0 to 61.5)-4.60 (-430.0 to 81.8)12.34 (-58.3 to 96.9)
Statistical analysis
  • Placebo vs Brivaracetam 150 mg/Day · stratified Wilcoxon Test · p = =0.942 (All hypotheses are tested at the 5 % level. The multiplicity scheme (hierarchical testing procedure) assures strong control of the type I error at the 5 % level.) · Hodges-lehmann-estimator of difference: 0.15 · 95% CI -26.12 to 24.96Difference versus Placebo was calculated.
  • Placebo vs Brivaracetam 5 mg/Day · stratified Wilcoxon Test · p = =0.105 (Tested at the 5 % level - given the primary endpoint and the three UMRS related secondary endpoints comparing placebo versus Brivaracetam (BRV) 150 mg/day are significant at the 5 % level (hierarchical testing procedure).) · Hodges-lehmann-estimator of difference: -18.05 · 95% CI -39.31 to 4.86Difference versus Placebo.
SecondaryPercent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5)

The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

Time frame:
Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Reported as:
Median · Percent change
Percent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5)
Percent changePlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
Percent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5)0.00 (-380.0 to 53.8)0.00 (-380.0 to 60.0)0.00 (-85.7 to 75.0)
Statistical analysis
  • Placebo vs Brivaracetam 150 mg/Day · stratified Wilcoxon Test · p = =0.672 (Tested at the 5 % level - given the Primary Outcome testing Placebo versus BRV 150 mg/day is significant at the 5 % level (hierarchical testing procedure).) · Hodges-lehmann-estimator of difference: 1.24 · 95% CI -21.90 to 31.06Difference versus Placebo.
  • Placebo vs Brivaracetam 5 mg/Day · stratified Wilcoxon Test · p = =0.806 (Tested at the 5 % level - given the primary endpoint testing Placebo versus Brivaracetam (BRV) 5 mg/day is significant at the 5 % level (hierarchical testing procedure).) · Hodges-lehmann-estimator of difference: 0.00 · 95% CI -33.33 to 18.75Difference versus Placebo.
SecondaryPercent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3)

The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

Time frame:
Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Reported as:
Median · Percent change
Percent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3)
Percent changePlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
Percent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3)0.00 (-300.0 to 100.0)43.44 (-300.0 to 100.0)0.00 (-300.0 to 100.0)
Statistical analysis
  • Placebo vs Brivaracetam 150 mg/Day · stratified Willcoxon Test · p = =0.549 (Tested at the 5 % level - given the Functional Disability Score comparing Placebo versus Brivaracetam (BRV) 150 mg/day is significant at the 5 % level (hierarchical testing procedure).) · Hodges-lehmann-estimator of difference: 0.00 · 95% CI -25.00 to 100.00Difference versus Placebo.
  • Placebo vs Brivaracetam 5 mg/Day · stratified Wilcoxon Test · p = =0.654 (Tested at the 5 % level - given the Functional Disability Score comparing Placebo versus Brivaracetam (BRV) 5 mg/day is significant at the 5 % level (hierarchical testing procedure).) · Hodges-lehmann-estimator of difference: 0.00 · 95% CI -50.00 to 66.67Difference versus Placebo.
SecondaryPercent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1)

The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit.

Time frame:
Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Reported as:
Median · Percent change
Percent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1)
Percent changePlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
Percent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1)-9.68 (-125.0 to 63.0)0.00 (-95.0 to 55.6)5.41 (-24.0 to 100.0)
Statistical analysis
  • Placebo vs Brivaracetam 150 mg/Day · stratified Wilcoxon Test · p = =0.037 (Tested at the 5 % level - given the Functional Disability Score comparing Placebo versus Brivaracetam (BRV) 150 mg/day is significant at the 5 % level (hierarchical testing procedure).) · Hodges-lehmann-estimator of difference: 14.29 · 95% CI -1.76 to 39.39Difference versus Placebo.
  • Placebo vs Brivaracetam 5 mg/Day · stratified Wilcoxon Test · p = =0.111 (Tested at the 5 % level - given the Functional Disability Score comparing Placebo versus Brivaracetam (BRV) 5 mg/day is significant at the 5 % level (hierarchical testing procedure).) · Hodges-lehmann-estimator of difference: 10.00 · 95% CI -5.56 to 30.00Difference versus Placebo.
SecondaryGlobal Evaluation Score (Investigator) at the End of Treatment Period

The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement).

Time frame:
End of Treatment Period (Week 14 or Early Discontinuation Visit)
Reported as:
Number · percentage of participants
Global Evaluation Score (Investigator) at the End of Treatment Period
percentage of participantsPlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
Marked improvement010.011.1
Moderate improvement11.1011.1
Slight improvement33.330.033.3
No change50.050.033.3
Slight worsening010.05.6
Moderate worsening005.6
Marked worsening5.600
Statistical analysis
  • Placebo vs Brivaracetam 5 mg/Day · Stratified Wilcoxon test · p = =0.931 (The Global Evaluation Scale by Investigator (I-GES) was compared between placebo and each dose at 5 % significance level independently from the previous secondary endpoints.)
  • Placebo vs Brivaracetam 150 mg/Day · Stratified Wilcoxon test · p = =0.253 (The Global Evaluation Scale by Investigator (I-GES) was compared between placebo and each dose at 5 % significance level independently from the previous secondary endpoints.)

Adverse events

Collected over Adverse Events (AEs) were collected from Visit 1 (Week -2) until final Visit 10 (Week 18).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/18 (11.1%)13/18 (72.2%)
Brivaracetam 5 mg/Day—3/20 (15%)13/20 (65%)
Brivaracetam 150 mg/Day—2/18 (11.1%)15/18 (83.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
AppendicitisInfections and infestations0/182/200/18
PyrexiaGeneral disorders1/180/200/18
Clavicle fractureInjury, poisoning and procedural complications0/180/201/18
ConvulsionNervous system disorders1/181/200/18
Grand mal convulsionNervous system disorders0/180/201/18
Status epilepticusNervous system disorders0/180/201/18
Myoclonic epilepsyNervous system disorders1/180/200/18
Attention-seeking behaviorPsychiatric disorders1/180/200/18
Most frequent other events
Showing 10 of 78
Most frequent other events
EventPlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/Day
HeadacheNervous system disorders7/183/202/18
SomnolenceNervous system disorders2/183/204/18
MyoclonusNervous system disorders1/184/203/18
FatigueGeneral disorders2/181/203/18
NasopharyngitisInfections and infestations3/181/201/18
TremorNervous system disorders3/180/201/18
Abdominal pain upperGastrointestinal disorders2/182/200/18
DiarrhoeaGastrointestinal disorders2/181/201/18
ConstipationGastrointestinal disorders2/180/201/18
Otitis externaInfections and infestations2/180/200/18

Baseline characteristics

The Baseline Analysis Population contains all randomized subjects who are identical with the Intent-To-Treat (ITT) population.

Age, Categorical
Age, Categorical(Participants)PlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/DayTotal Title
<=18 years0112
Between 18 and 65 years18191754
>=65 years0000
Age, Continuous
Age, Continuous(years)PlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/DayTotal Title
Mean34.3 ± 9.235.8 ± 10.933.7 ± 11.434.65 ± 10.38
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/DayTotal Title
Female1211932
Male69924
Region of Enrollment
Region of Enrollment(participants)PlaceboBrivaracetam 5 mg/DayBrivaracetam 150 mg/DayTotal Title
Serbia2226
France3238
United States2349
Canada4329
Finland3429
Russian Federation2338
Israel0022
Tunisia2305
08

Study locations

18 sites
  • 135
    San Francisco, California, United States
  • 133
    Gainesville, Florida, United States
  • 132
    New York, New York, United States
  • 131
    Charlottesville, Virginia, United States
  • 151
    Vancouver, British Columbia, Canada
  • 150
    Montreal, Quebec, Canada
  • 152
    Quebec, Canada
  • 100
    Helsinki, Finland
  • 122
    Bron, France
  • 121
    Lille, France
  • 120
    Paris, France
  • 170
    Tel Aviv, Israel
  • 141
    Moscow, Russian Federation
  • 142
    Saint Petersburg, Russian Federation
  • 143
    Samara, Russian Federation
  • 161
    Belgrade, Serbia
  • 162
    Belgrade, Serbia
  • 180
    La Manouba, Tunisia
09

References and documents

Publications

  • Ben-Menachem E, Baulac M, Hong SB, Cleveland JM, Reichel C, Schulz AL, Wagener G, Brandt C. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. Epilepsy Res. 2021 Feb;170:106526. doi: 10.1016/j.eplepsyres.2020.106526. Epub 2020 Dec 4. PubMed 33461041 ↗
  • Kalviainen R, Genton P, Andermann E, Andermann F, Magaudda A, Frucht SJ, Schlit AF, Gerard D, de la Loge C, von Rosenstiel P. Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016 Feb;57(2):210-21. doi: 10.1111/epi.13275. Epub 2015 Dec 15. PubMed 26666500 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 8 years 3 months after primary completion. A results delay was requested in Sep 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2006
First posted
Aug 24, 2006
Start
Nov 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results delay requested
Sep 9, 2009
Results first posted
Apr 13, 2016
Last update
May 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00368251
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Aug 24, 2006
Start date
Nov 2006
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Apr 13, 2016
Last update
May 31, 2023

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion